← SynDRA

COBICISTAT

SynDRA canonical compound SYN0029961 — structure-anchored drug synonym record

All known targets

• CYP3A4
• CYP3A43
• CYP3A5
• CYP3A7
• ABCG2
• SLCO1B3

Mechanisms of action (all sources)

• Cytochrome P450 inhibitor
• CYP3A4 INHIBITOR
• Cytochrome P450 3A inhibitor
• CYP3A5 INHIBITOR
• CYP3A43 INHIBITOR
• CYP3A7 INHIBITOR

Drug classes

• Anti-HIV Agents
• Anti-Infective Agents
• Anti-Retroviral Agents
• Antiviral Agents
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 Enzyme Inhibitors
• Enzyme Inhibitors
• Metabolic Side Effects of Drugs and Substances
• Cytochrome P450 2D6 Inhibitors
• P-Glycoprotein Inhibitors
• Organic Anion Transporting Polypeptide 1B1 Inhibitors
• Organic Anion Transporting Polypeptide 1B3 Inhibitors

ATC classes

• V03A · ALL OTHER THERAPEUTIC PRODUCTS
• DIRECT ACTING ANTIVIRALS

Cross-references

• PubChem CID: 25151504
• ChEMBL: CHEMBL2095208
• DrugBank: DB09065
• ChEBI: CHEBI:72291
• KEGG: D09881
• RxNorm: 1306284
• PDB: A1APA
• Wikipedia: Cobicistat
• TTD: D02VJP
• LINCS BRD: BRD-K51040301

Synonyms

• GS 9350
• tybost
• Cobicistat on silicon dioxide
• Cobicistat, (r,r,s)-
• GS-9350
• Cobicistat component of evotaz
• Cobicistat component of genvoya
• Cobicistat component of prezcobix
• Cobicistat component of rezolsta
• Cobicistat component of stribild
• Cobicistat component of symtuza
• Tybost
• Cobicistat (GS-9350)
• UNII-LW2E03M5PG
• Cobicistat,GS-9350
• CHEBI:72291
• LW2E03M5PG
• thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate
• 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate
• 1,3-thiazol-5-ylmethyl
• COBICISTAT, (R,R,S)-
• 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
• thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-yl)carbamate
• 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate
• 2,7,10,12-Tetraazatridecanoic acid, 12-methyl-13-(2-(1-methylethyl)-4-thiazolyl)-9-(2-(4-morpholinyl)ethyl)-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3R,6R,9S)-
• Cobicistat [USAN]
• Cobicistat [USAN:INN]
• cobicistatum
• 2,7,10,12-Tetraazatridecanoic acid, 12-methyl-13-[2-(1-methylethyl)-4-thiazolyl]-9-[2-(4-morpholinyl)ethyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3R,6R,9S)-
• Tybost (TN)
• COBICISTAT [MI]
• COBICISTAT [INN]
• COBICISTAT [JAN]
• Cobicistat; GS-9350
• COBICISTAT [VANDF]
• COBICISTAT [WHO-DD]
• Cobicistat (JAN/USAN/INN)
• GTPL7535

Reported adverse events

• Lactic acidosis
• Fanconi syndrome
• Rash
• Headache
• Nausea
• Fatigue
• Hepatomegaly
• Jaundice
• Ocular icterus
• Flatulence
• Abnormal dreams
• Dizziness